Abstract
Injectable forms of parathyroid hormone (PTH) and its N-terminal fragments are bone anabolic agents proven by randomized clinical trials. Alternate delivery forms of parathyroid hormone are under clinical or preclinical studies, including nasal, transdermal, and pulmonary formulations of PTH (1-34). Oral forms of PTH (1-34) and its analogs or orally active calcium sensing receptor antagonist, which induces PTH secretion from parathyroid gland, are also under development. PTH will be the one of the major therapeutic agents for osteoporosis treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
